These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24461299)

  • 21. Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors.
    Bahekar R; Panchal N; Soman S; Desai J; Patel D; Argade A; Gite A; Gite S; Patel B; Kumar J; S S; Patel H; Sundar R; Chatterjee A; Mahapatra J; Patel H; Ghoshdastidar K; Bandyopadhyay D; Desai RC
    Bioorg Chem; 2020 Jun; 99():103851. PubMed ID: 32334196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
    Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
    ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of substituted 3-anilino-quinolin-2(1H)-ones as PDK1 inhibitors.
    O'Brien NJ; Brzozowski M; Wilson DJ; Deady LW; Abbott BM
    Bioorg Med Chem; 2014 Jul; 22(14):3781-90. PubMed ID: 24856302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
    Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
    J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability.
    Kim H; Kim MK; Choo H; Chong Y
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3213-3215. PubMed ID: 27261178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.
    Forster M; Gehringer M; Laufer SA
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4229-4237. PubMed ID: 28844493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
    He L; Pei H; Lan T; Tang M; Zhang C; Chen L
    Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.
    Ma X; Diao Y; Ge H; Xu F; Zhu L; Zhao Z; Li H
    Bioorg Med Chem Lett; 2020 Apr; 30(8):127048. PubMed ID: 32122740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
    Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
    J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.
    Simov V; Deshmukh SV; Dinsmore CJ; Elwood F; Fernandez RB; Garcia Y; Gibeau C; Gunaydin H; Jung J; Katz JD; Kraybill B; Lapointe B; Patel SB; Siu T; Su H; Young JR
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1803-8. PubMed ID: 26927423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of highly potent, selective, covalent inhibitors of JAK3.
    Kempson J; Ovalle D; Guo J; Wrobleski ST; Lin S; Spergel SH; Duan JJ; Jiang B; Lu Z; Das J; Yang BV; Hynes J; Wu H; Tokarski J; Sack JS; Khan J; Schieven G; Blatt Y; Chaudhry C; Salter-Cid LM; Fura A; Barrish JC; Carter PH; Pitts WJ
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4622-4625. PubMed ID: 28927786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
    Zhu Y; Zheng X; Wang C; Sun X; Sun H; Ma T; Li Y; Liu K; Chen L; Ma X
    Bioorg Med Chem; 2020 Jan; 28(2):115254. PubMed ID: 31866272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.
    Soth M; Hermann JC; Yee C; Alam M; Barnett JW; Berry P; Browner MF; Frank K; Frauchiger S; Harris S; He Y; Hekmat-Nejad M; Hendricks T; Henningsen R; Hilgenkamp R; Ho H; Hoffman A; Hsu PY; Hu DQ; Itano A; Jaime-Figueroa S; Jahangir A; Jin S; Kuglstatter A; Kutach AK; Liao C; Lynch S; Menke J; Niu L; Patel V; Railkar A; Roy D; Shao A; Shaw D; Steiner S; Sun Y; Tan SL; Wang S; Vu MD
    J Med Chem; 2013 Jan; 56(1):345-56. PubMed ID: 23214979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.
    Forster M; Chaikuad A; Bauer SM; Holstein J; Robers MB; Corona CR; Gehringer M; Pfaffenrot E; Ghoreschi K; Knapp S; Laufer SA
    Cell Chem Biol; 2016 Nov; 23(11):1335-1340. PubMed ID: 27840070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome.
    Lynch SM; DeVicente J; Hermann JC; Jaime-Figueroa S; Jin S; Kuglstatter A; Li H; Lovey A; Menke J; Niu L; Patel V; Roy D; Soth M; Steiner S; Tivitmahaisoon P; Vu MD; Yee C
    Bioorg Med Chem Lett; 2013 May; 23(9):2793-800. PubMed ID: 23540648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines.
    de Vicente J; Lemoine R; Bartlett M; Hermann JC; Hekmat-Nejad M; Henningsen R; Jin S; Kuglstatter A; Li H; Lovey AJ; Menke J; Niu L; Patel V; Petersen A; Setti L; Shao A; Tivitmahaisoon P; Vu MD; Soth M
    Bioorg Med Chem Lett; 2014 Nov; 24(21):4969-75. PubMed ID: 25262541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors.
    Jaime-Figueroa S; De Vicente J; Hermann J; Jahangir A; Jin S; Kuglstatter A; Lynch SM; Menke J; Niu L; Patel V; Shao A; Soth M; Vu MD; Yee C
    Bioorg Med Chem Lett; 2013 May; 23(9):2522-6. PubMed ID: 23541670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490.
    Rashid S; Bibi N; Parveen Z; Shafique S
    J Biomol Struct Dyn; 2015; 33(11):2368-79. PubMed ID: 26017266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors.
    Yu RN; Chen CJ; Shu L; Yin Y; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Med Chem; 2019 Apr; 27(8):1646-1657. PubMed ID: 30853331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
    Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
    Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.